A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
Introduction Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) in...
Saved in:
| Published in | Diabetes therapy Vol. 15; no. 2; pp. 533 - 545 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cheshire
Springer Healthcare
01.02.2024
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1869-6953 1869-6961 |
| DOI | 10.1007/s13300-023-01526-x |
Cover
| Abstract | Introduction
Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes.
Methods
The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A
1c
(HbA
1c
) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA
1c
level by the end of the treatment period. Safety evaluations were performed for all participants.
Results
By the end of the 24-week treatment period, the mean HbA
1c
level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70–180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment.
Conclusion
Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.
Trial Registration
jRCTs2051190029 and NCT04018365. |
|---|---|
| AbstractList | Introduction Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. Methods The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A.sub.1c (HbA.sub.1c) level was [greater than or equal to] 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA.sub.1c level by the end of the treatment period. Safety evaluations were performed for all participants. Results By the end of the 24-week treatment period, the mean HbA.sub.1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70-180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Conclusion Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. Trial Registration jRCTs2051190029 and NCT04018365. Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes.INTRODUCTIONInsulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes.The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A1c (HbA1c) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA1c level by the end of the treatment period. Safety evaluations were performed for all participants.METHODSThe trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A1c (HbA1c) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA1c level by the end of the treatment period. Safety evaluations were performed for all participants.By the end of the 24-week treatment period, the mean HbA1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70-180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment.RESULTSBy the end of the 24-week treatment period, the mean HbA1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70-180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment.Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.CONCLUSIONOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.jRCTs2051190029 and NCT04018365.TRIAL REGISTRATIONjRCTs2051190029 and NCT04018365. Introduction Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. Methods The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A 1c (HbA 1c ) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA 1c level by the end of the treatment period. Safety evaluations were performed for all participants. Results By the end of the 24-week treatment period, the mean HbA 1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70–180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Conclusion Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. Trial Registration jRCTs2051190029 and NCT04018365. Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A (HbA ) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA level by the end of the treatment period. Safety evaluations were performed for all participants. By the end of the 24-week treatment period, the mean HbA level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70-180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. jRCTs2051190029 and NCT04018365. IntroductionInsulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes.MethodsThe trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A1c (HbA1c) level was ≥ 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA1c level by the end of the treatment period. Safety evaluations were performed for all participants.ResultsBy the end of the 24-week treatment period, the mean HbA1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70–180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment.ConclusionOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.Trial RegistrationjRCTs2051190029 and NCT04018365. Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing the efficacy of antidiabetes drugs for these rare conditions have been limited, however. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which lower glycemia independently of insulin action, have shown efficacy for type 2 diabetes with insulin resistance. We here investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin for treatment of insulin resistance syndrome and lipoatrophic diabetes. The trial was conducted at five academic centers in Japan and included seven patients with insulin resistance syndrome and one patient with lipoatrophic diabetes. Participants received 10 mg of empagliflozin daily. If the hemoglobin A.sub.1c (HbA.sub.1c) level was [greater than or equal to] 7.0% (52 mmol/mol) after 12 weeks, the dose was adjusted to 25 mg. The study duration was 24 weeks, and the primary outcome was the change in HbA.sub.1c level by the end of the treatment period. Safety evaluations were performed for all participants. By the end of the 24-week treatment period, the mean HbA.sub.1c level for all eight patients had decreased by 0.99 percentage points (10.8 mmol/mol) (95% confidence interval [CI], 0.59 to 1.38 percentage points, 6.6 to 14.9 mmol/mol) and the mean fasting plasma glucose concentration had declined by 63.9 mg/dL (3.55 mmol/L) (95% CI 25.5 to 102.3 mg/dL, 1.42 to 5.68 mmol/L). Continuous glucose monitoring revealed a reduction in mean glucose levels from 164.3 ± 76.1 to 137.6 ± 46.6 mg/dL (9.13 ± 4.23 to 7.65 ± 2.59 mmol/L) as well as an increase in the time in range (70-180 mg/dL) from 58.9 ± 36.1% to 70.8 ± 18.3%. Seventeen mild adverse events were recorded in five individuals throughout the study period. No severe events were reported. The mean body mass showed a slight decrease and the mean serum ketone body concentration showed a slight increase during treatment. Our results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes. |
| Audience | Academic |
| Author | Urakami, Tatsuhiko Omori, Takashi Kakei, Yasumasa Ebihara, Ken Suzuki, Junichi Imai, Junta Wada, Jun Hirota, Yushi Ogawa, Wataru Katagiri, Hideki |
| Author_xml | – sequence: 1 givenname: Yushi surname: Hirota fullname: Hirota, Yushi organization: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine – sequence: 2 givenname: Yasumasa surname: Kakei fullname: Kakei, Yasumasa organization: Clinical and Translational Research Center, Kobe University Hospital – sequence: 3 givenname: Junta surname: Imai fullname: Imai, Junta organization: Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine – sequence: 4 givenname: Hideki surname: Katagiri fullname: Katagiri, Hideki organization: Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine – sequence: 5 givenname: Ken surname: Ebihara fullname: Ebihara, Ken organization: Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University – sequence: 6 givenname: Jun surname: Wada fullname: Wada, Jun organization: Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University – sequence: 7 givenname: Junichi surname: Suzuki fullname: Suzuki, Junichi organization: Department of Pediatrics and Child Health, Nihon University School of Medicine – sequence: 8 givenname: Tatsuhiko surname: Urakami fullname: Urakami, Tatsuhiko organization: Department of Pediatrics and Child Health, Nihon University School of Medicine – sequence: 9 givenname: Takashi surname: Omori fullname: Omori, Takashi organization: Division of Clinical Biostatistics, Graduate School of Medicine, Kyoto University – sequence: 10 givenname: Wataru surname: Ogawa fullname: Ogawa, Wataru email: ogawa@med.kobe-u.ac.jp organization: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38216831$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt9uFCEYxSemxtbaF_DCkHhTk04dYGeGuTKbuuomu6nZ1mvCMB-7NAyswGjXB_I5Zd3-sY0pXEDg_A455LzM9qyzkGWvcXGKi6J-HzClRZEXhOYFLkmVXz_LDjCrmrxqKrx3ty_pfnYUwlWRBm2aBuMX2T5lBFeM4oPs9xjNBxO1BBvBn6DzNdh8JlowJ-hC26WBfOx7dOm1MMgpFFeAJkppKeQGCduhC6EgbrZXk34tlkYr435pmwgQsU-uSDmPFqC8kNH5Dfqok3uEgOZgjI5DQD91XKGpDYNJ3AKCDlFYCeh4Mv86XUxSvnevsudKmABHN-th9u3T5PLsSz47_zw9G89yWZUk5hVlbYsB6rIUoETVCKVI25WNrCvaMtIJRoDSkkELqiFVWXejklDCiq4umKT0MPuw810PbQ_d9le8MHztdS_8hjuh-cMbq1d86X5wXDDKGKuTw_GNg3ffBwiR9zrIFFVYcEPgpCFkNGIVLpP07SPplRu8Tfk4JYTWo4Y1o3vVUhjg2iqXHpZbUz6uGR7VFcbbZ0__o0qzg17LVB2l0_kD4M2_Se8i3lYjCdhOIL0LwYPiUkcRtdsG1yYl5tsi8l0ReSoi_1tEfp1Q8gi9dX8SojsoJLFdgr__jSeoP96S75s |
| CitedBy_id | crossref_primary_10_1111_jdi_14226 crossref_primary_10_3390_cells14060428 crossref_primary_10_1210_clinem_dgaf043 |
| Cites_doi | 10.1056/NEJM197604012941401 10.1007/s13340-020-00455-5 10.1056/NEJMra025261 10.2337/diab.42.5.696 10.1097/01.md.0000133625.73570.54 10.2337/dc18-0623 10.1111/jdi.13171 10.1056/NEJMoa2022190 10.1210/jc.2011-1159 10.1111/jdi.12401 10.1007/s13340-022-00570-5 10.1111/dom.12188 10.1007/s13300-023-01412-6 10.2147/DMSO.S130810 10.2337/dc15-1995 10.1016/j.ejphar.2021.174145 10.1111/j.1463-1326.2011.01517.x 10.1056/NEJMoa2107038 10.1210/er.2010-0020 10.1016/S2213-8587(13)70084-6 10.4158/EP09154.RA 10.1111/jdi.12825 10.1507/endocrj.EJ21-0110 10.1111/jdi.13241 10.1210/jc.2016-2466 10.1001/jama.2013.281053 10.1111/dom.13922 10.1111/dom.13012 10.1111/jdi.13026 10.4158/endp.19.1.v767575m65p5mr06 10.7326/L16-0372 10.1016/S2213-8587(14)70120-2 10.1056/NEJMoa2204233 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 Springer The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 Springer – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s13300-023-01526-x |
| DatabaseName | Springer Nature Open Access Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Link url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1869-6961 |
| EndPage | 545 |
| ExternalDocumentID | PMC10838887 A781476117 38216831 10_1007_s13300_023_01526_x |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Eli Lilly Japan funderid: http://dx.doi.org/10.13039/100014422 – fundername: Boehringer Ingelheim Japan funderid: http://dx.doi.org/10.13039/100017346 |
| GroupedDBID | --- -A0 0R~ 2VQ 3V. 4.4 40G 53G 5VS 7RV 7X7 8AO 8C1 8FI 8FJ AAKDD AAKKN AAYZH ABDBF ABEEZ ABUWG ACACY ACGFS ACIHN ACMJI ACUHS ACULB ADBBV ADINQ ADRAZ AEAQA AFGXO AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BKEYQ BKNYI BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR ITC K9- KQ8 LGEZI LOTEE M0R M48 M~E NADUK NAPCQ NXXTH O5R O5S O9- OK1 PIMPY PQQKQ PROAC RNS RPM RSV SISQX SMD SOJ U2A UKHRP ~JE AAYXX CITATION PHGZM PHGZT NPM PJZUB PPXIY PMFND 7XB 8FK DWQXO K9. PKEHL PQEST PQUKI PRINS PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-c652t-638bb1ee755aefa69aff2bd59c763b82da82e3358ebef92657d4523280d708c33 |
| IEDL.DBID | M48 |
| ISSN | 1869-6953 |
| IngestDate | Thu Aug 21 18:35:27 EDT 2025 Thu Sep 04 21:05:59 EDT 2025 Sat Aug 23 13:08:30 EDT 2025 Tue Jun 17 22:24:14 EDT 2025 Tue Jun 10 21:14:32 EDT 2025 Mon Jul 21 06:06:05 EDT 2025 Thu Apr 24 22:56:55 EDT 2025 Tue Jul 01 04:25:51 EDT 2025 Fri Feb 21 02:40:25 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Empagliflozin Genetic insulin resistance syndrome Type A insulin resistance syndrome Lipoatrophic diabetes SGLT2 inhibitor Type B insulin resistance syndrome |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c652t-638bb1ee755aefa69aff2bd59c763b82da82e3358ebef92657d4523280d708c33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s13300-023-01526-x |
| PMID | 38216831 |
| PQID | 3223749894 |
| PQPubID | 2034778 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10838887 proquest_miscellaneous_2922448615 proquest_journals_3223749894 gale_infotracmisc_A781476117 gale_infotracacademiconefile_A781476117 pubmed_primary_38216831 crossref_citationtrail_10_1007_s13300_023_01526_x crossref_primary_10_1007_s13300_023_01526_x springer_journals_10_1007_s13300_023_01526_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-01 |
| PublicationDateYYYYMMDD | 2024-02-01 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cheshire |
| PublicationPlace_xml | – name: Cheshire – name: United States – name: Tarporley |
| PublicationSubtitle | Research, treatment and education of diabetes and related disorders |
| PublicationTitle | Diabetes therapy |
| PublicationTitleAbbrev | Diabetes Ther |
| PublicationTitleAlternate | Diabetes Ther |
| PublicationYear | 2024 |
| Publisher | Springer Healthcare Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Healthcare – name: Springer – name: Springer Nature B.V |
| References | Garg (CR10) 2004; 350 Grempler, Thomas, Eckhardt (CR16) 2012; 14 Ogawa, Hirota (CR30) 2019; 10 Kahn, Flier, Bar (CR3) 1976; 294 Araki, Watada, Uchigata (CR33) 2020; 22 Ogawa, Araki, Ishigaki (CR2) 2022; 13 Kawana, Imai, Sawada, Yamada, Katagiri (CR13) 2017; 166 Packer, Anker, Butler (CR19) 2020; 383 CR17 Anker, Butler, Filippatos (CR18) 2021; 385 Tanaka, Kusakabe, Ebihara (CR12) 2021; 68 Hamaguchi, Hirota, Takeuchi (CR6) 2018; 9 Peters, Henry, Thakkar (CR28) 2016; 39 Zhu, Lin, Li, Hu, Cai, Ji (CR23) 2021; 903 Kushi, Hirota, Ogawa (CR7) 2020; 12 Semple, Savage, Cochran, Gorden, O’Rahilly (CR1) 2011; 32 Yagi, Toda, Mitani, Kotobuki, Ogawa (CR26) 2023; 14 Chiquette, Oral, Garg, Araújo-Vilar, Dhankhar (CR9) 2017; 10 Bonora, Avogaro, Fadini (CR27) 2018; 20 Ogawa, Sakaguchi (CR29) 2016; 7 Handelsman, Ora, Bloomgarden (CR14) 2013; 19 Kuzuya, Matsuura, Sakamoto (CR34) 1993; 42 Garg (CR8) 2011; 96 (CR21) 2013; 310 Nagashima, Wakabayashi, Saito (CR20) 2020; 11 Roden, Weng, Eilbracht (CR24) 2013; 1 CR25 Mathieu, Dandona, Gillard (CR32) 2018; 41 CR22 Chan, Oral (CR15) 2010; 16 Musso, Cochran, Moran (CR4) 2004; 83 Brown, Araujo-Vilar, Cheung (CR11) 2016; 101 Kovacs, Seshiah, Swallow (CR31) 2014; 16 Takeuchi, Ishigaki, Hirota (CR5) 2020; 11 AL Peters (1526_CR28) 2016; 39 H Kuzuya (1526_CR34) 1993; 42 1526_CR25 1526_CR22 World Medical Association (1526_CR21) 2013; 310 M Packer (1526_CR19) 2020; 383 CR Kahn (1526_CR3) 1976; 294 CS Kovacs (1526_CR31) 2014; 16 N Yagi (1526_CR26) 2023; 14 W Ogawa (1526_CR29) 2016; 7 W Ogawa (1526_CR2) 2022; 13 R Kushi (1526_CR7) 2020; 12 C Musso (1526_CR4) 2004; 83 T Hamaguchi (1526_CR6) 2018; 9 SD Anker (1526_CR18) 2021; 385 W Ogawa (1526_CR30) 2019; 10 T Tanaka (1526_CR12) 2021; 68 BM Bonora (1526_CR27) 2018; 20 1526_CR17 JL Chan (1526_CR15) 2010; 16 Y Kawana (1526_CR13) 2017; 166 E Chiquette (1526_CR9) 2017; 10 R Grempler (1526_CR16) 2012; 14 E Araki (1526_CR33) 2020; 22 M Roden (1526_CR24) 2013; 1 S Nagashima (1526_CR20) 2020; 11 T Takeuchi (1526_CR5) 2020; 11 A Garg (1526_CR8) 2011; 96 A Garg (1526_CR10) 2004; 350 C Mathieu (1526_CR32) 2018; 41 RJ Brown (1526_CR11) 2016; 101 RK Semple (1526_CR1) 2011; 32 Y Handelsman (1526_CR14) 2013; 19 X Zhu (1526_CR23) 2021; 903 |
| References_xml | – ident: CR22 – volume: 294 start-page: 739 year: 1976 end-page: 45 ident: CR3 article-title: The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man publication-title: N Engl J Med doi: 10.1056/NEJM197604012941401 – volume: 12 start-page: 62 year: 2020 end-page: 67 ident: CR7 article-title: Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway publication-title: Diabetol Int doi: 10.1007/s13340-020-00455-5 – volume: 350 start-page: 1220 year: 2004 end-page: 1234 ident: CR10 article-title: Acquired and inherited lipodystrophies publication-title: N Engl J Med doi: 10.1056/NEJMra025261 – volume: 42 start-page: 696 year: 1993 end-page: 705 ident: CR34 article-title: Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes publication-title: Diabetes doi: 10.2337/diab.42.5.696 – volume: 83 start-page: 209 year: 2004 end-page: 222 ident: CR4 article-title: Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective publication-title: Medicine (Baltimore) doi: 10.1097/01.md.0000133625.73570.54 – volume: 41 start-page: 1938 year: 2018 end-page: 46 ident: CR32 article-title: DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial publication-title: Diabetes Care doi: 10.2337/dc18-0623 – volume: 11 start-page: 603 year: 2020 end-page: 616 ident: CR5 article-title: Clinical characteristics of insulin resistance syndromes: a nationwide survey in Japan publication-title: J Diabetes Investig doi: 10.1111/jdi.13171 – volume: 383 start-page: 1413 year: 2020 end-page: 24 ident: CR19 article-title: EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 96 start-page: 3313 year: 2011 end-page: 3325 ident: CR8 article-title: Clinical review: Lipodystrophies: genetic and acquired body fat disorders publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-1159 – ident: CR25 – volume: 7 start-page: 135 year: 2016 end-page: 138 ident: CR29 article-title: Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors publication-title: J Diabetes Investig doi: 10.1111/jdi.12401 – volume: 13 start-page: 337 year: 2022 end-page: 343 ident: CR2 article-title: New classification and diagnostic criteria for insulin resistance syndrome publication-title: Diabetol Int doi: 10.1007/s13340-022-00570-5 – volume: 16 start-page: 147 year: 2014 end-page: 58 ident: CR31 article-title: EMPA-REG PIO™ Trial Investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial publication-title: Diabetes Obes Metab doi: 10.1111/dom.12188 – volume: 14 start-page: 1345 year: 2023 end-page: 1356 ident: CR26 article-title: A qualitative research study of experiences and perceptions of people living with insulin resistance syndrome or lipoatrophic diabetes in Japan publication-title: Diabetes Ther doi: 10.1007/s13300-023-01412-6 – volume: 10 start-page: 375 year: 2017 end-page: 383 ident: CR9 article-title: Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S130810 – volume: 39 start-page: 532 year: 2016 end-page: 538 ident: CR28 article-title: Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes publication-title: Diabetes Care doi: 10.2337/dc15-1995 – volume: 903 year: 2021 ident: CR23 article-title: SGLT2i increased the plasma fasting glucagon level in patients with diabetes: a meta-analysis publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2021.174145 – volume: 14 start-page: 83 year: 2012 end-page: 90 ident: CR16 article-title: Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2011.01517.x – volume: 385 start-page: 1451 year: 2021 end-page: 61 ident: CR18 article-title: EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction publication-title: N Engl J Med doi: 10.1056/NEJMoa2107038 – volume: 32 start-page: 498 year: 2011 end-page: 514 ident: CR1 article-title: Genetic syndromes of severe insulin resistance publication-title: Endocr Rev doi: 10.1210/er.2010-0020 – ident: CR17 – volume: 1 start-page: 208 year: 2013 end-page: 19 ident: CR24 article-title: EMPA-REG MONO Trial Investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised double-blind placebo-controlled phase 3 trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70084-6 – volume: 16 start-page: 310 year: 2010 end-page: 323 ident: CR15 article-title: Clinical classification and treatment of congenital and acquired lipodystrophy publication-title: Endocr Pract doi: 10.4158/EP09154.RA – volume: 9 start-page: 1224 year: 2018 end-page: 1227 ident: CR6 article-title: Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor publication-title: J Diabetes Investig doi: 10.1111/jdi.12825 – volume: 68 start-page: 1027 year: 2021 end-page: 1042 ident: CR12 article-title: Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES) publication-title: Endocr J doi: 10.1507/endocrj.EJ21-0110 – volume: 11 start-page: 1363 year: 2020 end-page: 1365 ident: CR20 article-title: Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome publication-title: J Diabetes Investig doi: 10.1111/jdi.13241 – volume: 101 start-page: 4500 year: 2016 end-page: 4511 ident: CR11 article-title: The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-2466 – volume: 310 start-page: 2191 year: 2013 end-page: 2194 ident: CR21 article-title: World Medical Association Declaration of Helsinki: ethical principles for medical research publication-title: JAMA doi: 10.1001/jama.2013.281053 – volume: 22 start-page: 540 year: 2020 end-page: 548 ident: CR33 article-title: Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial publication-title: Diabetes Obes Metab doi: 10.1111/dom.13922 – volume: 20 start-page: 25 year: 2018 end-page: 33 ident: CR27 article-title: Sodium-glucose cotransporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature publication-title: Diabetes Obes Metab doi: 10.1111/dom.13012 – volume: 10 start-page: 879 year: 2019 end-page: 882 ident: CR30 article-title: Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis in patients with type 1 diabetes: metabolic imbalance as an underlying mechanism publication-title: J Diabetes Investig doi: 10.1111/jdi.13026 – volume: 19 start-page: 107 year: 2013 end-page: 16 ident: CR14 article-title: American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy—an AACE consensus statement publication-title: Endocr Pract doi: 10.4158/endp.19.1.v767575m65p5mr06 – volume: 166 start-page: 450 year: 2017 end-page: 451 ident: CR13 article-title: Sodium-glucose cotransporter 2 inhibitor improves complications of lipodystrophy: a case report publication-title: Ann Intern Med doi: 10.7326/L16-0372 – volume: 83 start-page: 209 year: 2004 ident: 1526_CR4 publication-title: Medicine (Baltimore) doi: 10.1097/01.md.0000133625.73570.54 – volume: 22 start-page: 540 year: 2020 ident: 1526_CR33 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13922 – volume: 310 start-page: 2191 year: 2013 ident: 1526_CR21 publication-title: JAMA doi: 10.1001/jama.2013.281053 – volume: 1 start-page: 208 year: 2013 ident: 1526_CR24 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70084-6 – volume: 14 start-page: 83 year: 2012 ident: 1526_CR16 publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2011.01517.x – volume: 42 start-page: 696 year: 1993 ident: 1526_CR34 publication-title: Diabetes doi: 10.2337/diab.42.5.696 – volume: 350 start-page: 1220 year: 2004 ident: 1526_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMra025261 – ident: 1526_CR25 doi: 10.1016/S2213-8587(14)70120-2 – ident: 1526_CR17 doi: 10.1056/NEJMoa2204233 – volume: 294 start-page: 739 year: 1976 ident: 1526_CR3 publication-title: N Engl J Med doi: 10.1056/NEJM197604012941401 – volume: 41 start-page: 1938 year: 2018 ident: 1526_CR32 publication-title: Diabetes Care doi: 10.2337/dc18-0623 – volume: 16 start-page: 310 year: 2010 ident: 1526_CR15 publication-title: Endocr Pract doi: 10.4158/EP09154.RA – volume: 903 year: 2021 ident: 1526_CR23 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2021.174145 – volume: 10 start-page: 879 year: 2019 ident: 1526_CR30 publication-title: J Diabetes Investig doi: 10.1111/jdi.13026 – volume: 96 start-page: 3313 year: 2011 ident: 1526_CR8 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2011-1159 – volume: 9 start-page: 1224 year: 2018 ident: 1526_CR6 publication-title: J Diabetes Investig doi: 10.1111/jdi.12825 – volume: 39 start-page: 532 year: 2016 ident: 1526_CR28 publication-title: Diabetes Care doi: 10.2337/dc15-1995 – volume: 16 start-page: 147 year: 2014 ident: 1526_CR31 publication-title: Diabetes Obes Metab doi: 10.1111/dom.12188 – volume: 383 start-page: 1413 year: 2020 ident: 1526_CR19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 385 start-page: 1451 year: 2021 ident: 1526_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa2107038 – volume: 13 start-page: 337 year: 2022 ident: 1526_CR2 publication-title: Diabetol Int doi: 10.1007/s13340-022-00570-5 – volume: 11 start-page: 1363 year: 2020 ident: 1526_CR20 publication-title: J Diabetes Investig doi: 10.1111/jdi.13241 – volume: 12 start-page: 62 year: 2020 ident: 1526_CR7 publication-title: Diabetol Int doi: 10.1007/s13340-020-00455-5 – volume: 101 start-page: 4500 year: 2016 ident: 1526_CR11 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-2466 – volume: 32 start-page: 498 year: 2011 ident: 1526_CR1 publication-title: Endocr Rev doi: 10.1210/er.2010-0020 – volume: 10 start-page: 375 year: 2017 ident: 1526_CR9 publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S130810 – ident: 1526_CR22 – volume: 11 start-page: 603 year: 2020 ident: 1526_CR5 publication-title: J Diabetes Investig doi: 10.1111/jdi.13171 – volume: 68 start-page: 1027 year: 2021 ident: 1526_CR12 publication-title: Endocr J doi: 10.1507/endocrj.EJ21-0110 – volume: 14 start-page: 1345 year: 2023 ident: 1526_CR26 publication-title: Diabetes Ther doi: 10.1007/s13300-023-01412-6 – volume: 19 start-page: 107 year: 2013 ident: 1526_CR14 publication-title: Endocr Pract doi: 10.4158/endp.19.1.v767575m65p5mr06 – volume: 166 start-page: 450 year: 2017 ident: 1526_CR13 publication-title: Ann Intern Med doi: 10.7326/L16-0372 – volume: 20 start-page: 25 year: 2018 ident: 1526_CR27 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13012 – volume: 7 start-page: 135 year: 2016 ident: 1526_CR29 publication-title: J Diabetes Investig doi: 10.1111/jdi.12401 |
| SSID | ssj0000399911 |
| Score | 2.3288565 |
| Snippet | Introduction
Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials... Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials assessing... Introduction Insulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials... IntroductionInsulin resistance syndrome and lipoatrophic diabetes are characterized by severe insulin resistance and are often refractory to treatment. Trials... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 533 |
| SubjectTerms | Blood sugar monitoring Body fat Cardiology Clinical trials Dextrose Diabetes Diabetes therapy Drug dosages Drug therapy Endocrinology Genes Glucose Glycosylated hemoglobin Hypoglycemic agents Insulin resistance Internal Medicine Medical colleges Medicine Medicine & Public Health Metabolism Original Research Pharmaceutical industry Statistical analysis Type 2 diabetes Weight control |
| SummonAdditionalLinks | – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA66gvgi3u3uKhEEFSfYpm2aPMmwzLIrjsheYN9K06Y6UNp12oEdf5C_03PSTMcOuG8z5EKac_uSnHwh5C3XkV_kWcFCYXIWBb5i2i_wJhfg3yJRsTaW7fObOLmMvlzFV27DrXVplRufaB110eS4R_4JFC9MIqQL_3z9i-GrUXi66p7QuEvuBeCD0TDlUTDssfghwh-75pJCMaHi0N2b6W_PwVreZxC0YD0dc8FuRrFp10P_E6J20yd3zlBtaDp-RB46TEmnvRI8JndM_YTcn7tT86fkz5Tae7bYk1lOKCaRsK-ZNtWEnkOPlWEgb3qBukibkgImpDOklsjyNc3qgp5npenWWDQD7_GjWpRV83tRQwuXpU4B-tIzUy7t6z1r6vJsWjpHvs9u1VLc76WnfeI71GwRtoK-0fez-ffTsxnMzYdn5PJ4dnF0wtz7DCwXMe8YmK7WgTFJHGemzITKypLrIlY5OC0teZFJbsIwlqAopeIiTooI1r1c-kXiyzwMn5O9uqnNS0KjXOnE-hcFXqWU2igOQFTB_yyCHx4JNpJJc0dejm9oVOmWdhmlmYI0UyvN9MYjH4c21z11x62136HAU7Rr6BlmuL-eAONDhqx0itxgiQiCxCOHo5pgj_m4eKMyqfMHbbrVXo-8GYqxJea41aZZtSlXAKciCRDTIy96DRvGHUoeCBkGHpEj3RsqIEv4uKRe_LRs4QGAbAmhxCOTjZpux_X_-di__TMOyAMO8K7PXz8ke91yZV4BPOv0a2uDfwEbGTPU priority: 102 providerName: ProQuest – databaseName: Springer Open Access Hybrid - NESLI2 2011-2012 dbid: 40G link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9QwEA5ygvhFfLfeKREEFTfQpk2bfFyk5524IvcC9y00bXoulK5su3DrD_J3OpO-rF1U8NsumYSQmcw8aWaeEPKam8gv8qxgYWxzFgW-YsYvsJIL8G-RKGGsY_v8Ep9cRp-uxFVfFNYM2e7DlaTz1LtiNzh6-wxiDBx_BY8ZIMfbSCeG7xZE_sfxy4ofIuhxJy0ZKxYrEfbVMn8eZhKR9v3yb4FpP2ly7-bUBaTj--RejyTpvFP9A3LL1g_JnUV_V_6I_JxTV12LI9n1jGLqCPucGVvN6DmMWFkGWqYXaIF0VVJAgjRFQoks39KsLuh5Vtp2i00p-IzrallWqx_LGnr0uekUAC89s-XavdmzpX12TUMXyPLZbhqKX3npaZfuDpINglWwMvo2XXw9PUthbd49JpfH6cWHE9a_ysDyWPCWwYY1JrA2ESKzZRarrCy5KYTKwVUZyYtMchuGQoJ5lIrHIikiOO1y6ReJL_MwfEIO6lVtnxEa5cokzqso8CWlNFZxgJ8K_mcR_PBIMGhG5z1lOb6cUekd2TJqU4M2tdOmvvHI-7HP946w45_Sb1DhGnczjAwr3BUlwPyQF0vPkREsiYMg8cjRRBJ2YT5tHkxG916g0eAswyRCinuPvBqbsSdmttV2tWk0VwCiIgnA0iNPOwsb5x1KHsQyDDwiJ7Y3CiA3-LSlXn5zHOEBQGsJAcQjs8FMd_P6-3o8_z_xQ3KXA8jrstiPyEG73tgXANJa89LtyV-ayjEm priority: 102 providerName: Springer Nature |
| Title | A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01) |
| URI | https://link.springer.com/article/10.1007/s13300-023-01526-x https://www.ncbi.nlm.nih.gov/pubmed/38216831 https://www.proquest.com/docview/3223749894 https://www.proquest.com/docview/2922448615 https://pubmed.ncbi.nlm.nih.gov/PMC10838887 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-6Fkpfxr7nrQsaDLaxuNiyLUsPY2TBXTuWUtIG8mYsW94CxtnyAc3-oP2du_NHsoRuD3sRMfqwkH66-118dwJ4xbXvZGmS2Z4wqe27jrK1k1EkF_LfLFSBNlW2zwtxNvI_j4PxHrTXHTULOL_VtKP7pEaz4uTmx-oDHvj3mzA4NModG7UPGsYBFzZyygPUTIKMsUFD9yvJ7BEdqmwwKZQtVOA1cTS3D3MEh57krpCeu6W2doX3H9pr17Ny5_NqpbVO78Hdhm6yXo2P-7BnygdwOGg-qD-EXz1WheDSSGbWZeRfYn9JtCm67ApHLIyNUGDXBFM2zRnSRRZR1okkXbGkzNhVkpvFiqoiFCxfi0leTH9OSuzROLAzZMVsaPJZdbHPijUuOHM2oFSgi-Wc0V_B7Lz2iceWc2K0CEX2Jhpcng8jXKa3j2B0Gl33z-zm6gY7FQFf2HiqtXaNCYMgMXkiVJLnXGeBSlGeacmzRHLjeYFEDOWKiyDMfDSJuXSy0JGp5z2G_XJamqfA_FTpsBI9CgVOLrVRHDmqwufExx8WuO3OxGmT15yu1yjiTUZm2tgYNzauNja-seDdus_3OqvHP1u_pg2PCYQ4Mq5wHbmA86PkWXGP0oaFwnVDC463WuJRTberW8jELdJjlKhe6FMefAterqupJ7m_lWa6nMdcIdPyJbJPC57UCFvPu0WoBXILe-sGlEB8u6acfKsSibvIvyVqGQu6LUw38_r7ejz7_zc9hyOOrLB2ez-G_cVsaV4gq1voDtzxnU9YhuMQS9l3O3DwMbq4HOJTn_tUin6nOtBYjnjvN1QCS5g |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELaqIgEXxJstBYwEAkQsdr0v-4BQBKkSmlSoTaXc3PWul0aKNiW7EQ0_iCO_kZl9hUSit94S-SGv5_P483hmTMgrrj07iaOEuYGJmefYkmk7wUgu4L9JKH1tymyfR0H_1Ps68Sc75E8TC4NulY1OLBV1Mo_RRv4BgOeGHqYL_3Txg-GrUXi72jyhUcHi0Kx-wpEt_zj4AvJ9zflBb_y5z-pXBVgc-LxgADitHWNC349MGgUySlOuE1_GsNS04EkkuHFdX8DnpZIHfph4cFrjwk5CW8RoAAWVf8NDyzisn3AStjYd20W6VZ7xRCBZIH23jtOpovVcF8O4OTow-Txglxt74faO8M-WuO2uuXVnW26FB3fJnZrD0m4Funtkx2T3yc1RfUv_gPzu0jKuF3syiw5FpxU2jLSZdegJ9DgzDPBFx4h9Ok8pcFDaw1QWUbyiUZbQkyg1xQqLeqCtvs-m6Wz-a5pBi9orngLVpscmXZSvBa1o7deT0xHmFy2WOUX7Mh1UjvZQM0eaDPimb3ujb4PjHszNu4fk9Fok94jsZvPMPCHUi6UOS30mQYulQhvJgfhK-B958MMiTiMZFdfJ0vHNjplap3lGaSqQpiqlqS4t8r5tc1GlCrmy9hsUuEI9Aj3DDFfhEDA-zMilupiLLAwcJ7TI_kZNWP_xZnEDGVXrn1ytV4tFXrbF2BJ96jIzX-aKS6BvngBKa5HHFcLacbuCO4FwHYuIDey1FTAr-WZJNj0vs5M7QOoFbF0W6TQwXY_r__Oxd_VnvCC3-uPRUA0HR4dPyW0O1LLynd8nu8ViaZ4BNSz083I9UnJ23QrgL2PKcT4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIU28IO4EBhgJBIhaS-xc7AeEKtZqZes07SL1zcSJA5WqZDStWPlB_Ah-Hefk0tJK7G1vrXyR43PxZ_ucz4S85sZ30yROmQhtwnzPVcy4KWZyAf5NIxUYW7F9HocHF_6XUTDaIn_aXBgMq2x9YuWo0yLBM_I9UDwR-UgXvpc1YREn-_1Plz8YviCFN63tcxq1ihzaxU_YvpUfB_sg6zec93vnnw9Y88IAS8KAzxgonzGetVEQxDaLQxVnGTdpoBIwOyN5GktuhQgkfGqmeBhEqQ87Ny7dNHJlgoeh4P5vRQJQFdhSNIqW5zuuQOhV7fdkqFioAtHk7NSZe0JgSjfHYKaAh-xqbV3cXB3-WR43Qzc37m-rZbF_l9xp8Czt1gp4j2zZ_D7ZGTY39g_I7y6tcnyxJzvtUAxgYUexsZMOPYMeJ5aBrtFztANaZBTwKO0hrUWcLGicp_QszuxsgUU98FzfJuNsUvwa59CiiZCnALvpqc2m1ctBC9rE-JR0iFyjs3lJ8ayZDuqge6hZImQGXafvesOTwWkP5ub9Q3JxI5J7RLbzIrdPCPUTZaLKtynwaJk0VnEAwQr-xz78cIjXSkYnDXE6vt8x0SvKZ5SmBmnqSpr6yiEflm0ua9qQa2u_RYFr9CnQM8xwnRoB40N2Lt1FXrIo9LzIIbtrNcEXJOvFrcroxheVemU5Dnm1LMaWGF-X22Jeaq4AyvkS4K1DHtcathy3kNwLpfAcItd0b1kBGcrXS_Lx94qp3AOAL2EZc0inVdPVuP4_H0-v_4yXZAdMXx8Njg-fkdscUGYdRr9LtmfTuX0OKHFmXlTmSMnXm7b_vxJqdX0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Multicenter%2C+Open-Label%2C+Single-Arm+Trial+of+the+Efficacy+and+Safety+of+Empagliflozin+Treatment+for+Refractory+Diabetes+Mellitus+with+Insulin+Resistance+%28EMPIRE-01%29&rft.jtitle=Diabetes+therapy&rft.au=Hirota%2C+Yushi&rft.au=Kakei%2C+Yasumasa&rft.au=Imai%2C+Junta&rft.au=Katagiri%2C+Hideki&rft.date=2024-02-01&rft.pub=Springer+Healthcare&rft.issn=1869-6953&rft.eissn=1869-6961&rft.volume=15&rft.issue=2&rft.spage=533&rft.epage=545&rft_id=info:doi/10.1007%2Fs13300-023-01526-x&rft_id=info%3Apmid%2F38216831&rft.externalDocID=PMC10838887 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1869-6953&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1869-6953&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1869-6953&client=summon |